Gamble Jones Investment Counsel Has $1.54 Million Stock Position in Eli Lilly And Co (NYSE:LLY)

Gamble Jones Investment Counsel decreased its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 1.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,749 shares of the company’s stock after selling 150 shares during the quarter. Gamble Jones Investment Counsel’s holdings in Eli Lilly And Co were worth $1,538,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Buckingham Capital Management Inc. increased its position in shares of Eli Lilly And Co by 84.1% during the first quarter. Buckingham Capital Management Inc. now owns 3,713 shares of the company’s stock worth $482,000 after acquiring an additional 1,696 shares during the period. Private Trust Co. NA increased its holdings in Eli Lilly And Co by 3.8% in the second quarter. Private Trust Co. NA now owns 6,314 shares of the company’s stock valued at $699,000 after buying an additional 233 shares during the last quarter. Pensionfund DSM Netherlands purchased a new position in Eli Lilly And Co in the second quarter valued at $3,545,000. Pensionfund Sabic purchased a new position in Eli Lilly And Co in the second quarter valued at $2,382,000. Finally, Verde Servicos Internacionais S.A. increased its holdings in Eli Lilly And Co by 36.8% in the second quarter. Verde Servicos Internacionais S.A. now owns 49,756 shares of the company’s stock valued at $5,512,000 after buying an additional 13,385 shares during the last quarter. Institutional investors own 77.22% of the company’s stock.

In other news, CEO David A. Ricks acquired 4,615 shares of the company’s stock in a transaction on Friday, October 25th. The shares were bought at an average price of $108.38 per share, with a total value of $500,173.70. Following the completion of the acquisition, the chief executive officer now owns 157,405 shares in the company, valued at approximately $17,059,553.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Alfonso G. Zulueta sold 19,500 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $112.91, for a total value of $2,201,745.00. Following the transaction, the senior vice president now directly owns 38,306 shares in the company, valued at approximately $4,325,130.46. The disclosure for this sale can be found here. In the last ninety days, insiders have acquired 8,405 shares of company stock worth $909,004 and have sold 614,373 shares worth $70,546,895. Company insiders own 0.11% of the company’s stock.

Several equities analysts recently commented on LLY shares. Bank of America started coverage on Eli Lilly And Co in a report on Wednesday, October 16th. They issued a “buy” rating and a $133.00 target price on the stock. UBS Group dropped their target price on Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating on the stock in a report on Thursday, October 17th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Eli Lilly And Co presently has an average rating of “Buy” and an average target price of $130.03.

Shares of LLY stock traded up $0.76 during mid-day trading on Friday, hitting $113.53. 2,190,598 shares of the stock were exchanged, compared to its average volume of 7,683,282. The stock’s fifty day simple moving average is $110.61 and its two-hundred day simple moving average is $112.67. The stock has a market capitalization of $106.81 billion, a price-to-earnings ratio of 20.46, a P/E/G ratio of 1.82 and a beta of 0.16. Eli Lilly And Co has a 12-month low of $101.36 and a 12-month high of $132.13. The company has a debt-to-equity ratio of 4.09, a quick ratio of 0.88 and a current ratio of 1.17.

Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings data on Wednesday, October 23rd. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.43 by $0.05. The company had revenue of $5.48 billion for the quarter, compared to analyst estimates of $5.50 billion. Eli Lilly And Co had a return on equity of 107.99% and a net margin of 35.10%. The business’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter last year, the company posted $1.39 earnings per share. On average, research analysts expect that Eli Lilly And Co will post 5.78 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a dividend of $0.645 per share. This represents a $2.58 annualized dividend and a dividend yield of 2.27%. The ex-dividend date is Thursday, November 14th. Eli Lilly And Co’s payout ratio is 46.49%.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: Stock Symbols, CUSIP and Other Stock Identifiers

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.